In thyroid cancer, programmed cell death protein 1 (PD-1) therapy resistance is mediated by tumor-associated macrophage (TAM)- derived EVs through the delivery of miR-21-5p, which inhibits methyltransferase-like 3 (METTL3) [102]. The gene discussed is METTL3; the disease is thyroid gland carcinoma.